FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1991562979> ?p ?o ?g. }

• W1991562979 endingPage "997" @default.
• W1991562979 startingPage "991" @default.
• W1991562979 abstract "We treated 28 patients (16 women and 12 men) who had essential tremor with methazolamide. Their median age was 69 years (range, 34 to 89 years), and the median duration of tremor was 16 years (range, less than 1 to 69 years). Fifteen cases were familial and 13 were sporadic. Improvement in 10 patients who continued taking the drug ranged from moderate to complete relief. In addition, four patients had marked improvement and two had moderate improvement but discontinued use of the drug because of side effects. Five patients with a mild response and seven with no response also discontinued methazolamide therapy. The maximal mean daily dose was 203 mg for all patients and 129 mg (maintenance dose) for the patients who continued taking the drug. Side effects consisted primarily of somnolence, nausea, epigastric discomfort, anorexia, paresthesias, and numbness. No aplastic anemia was noted in any of the patients. The median duration of follow-up was 6 months (range, 10 weeks to 29 months). The therapeutic effect seemed unrelated to a family history of tremor, the effect of alcohol, or the responsiveness to propranolol or primidone. Methazolamide may be an effective drug in the treatment of some patients with essential tremor, particularly those with head and voice tremor. We treated 28 patients (16 women and 12 men) who had essential tremor with methazolamide. Their median age was 69 years (range, 34 to 89 years), and the median duration of tremor was 16 years (range, less than 1 to 69 years). Fifteen cases were familial and 13 were sporadic. Improvement in 10 patients who continued taking the drug ranged from moderate to complete relief. In addition, four patients had marked improvement and two had moderate improvement but discontinued use of the drug because of side effects. Five patients with a mild response and seven with no response also discontinued methazolamide therapy. The maximal mean daily dose was 203 mg for all patients and 129 mg (maintenance dose) for the patients who continued taking the drug. Side effects consisted primarily of somnolence, nausea, epigastric discomfort, anorexia, paresthesias, and numbness. No aplastic anemia was noted in any of the patients. The median duration of follow-up was 6 months (range, 10 weeks to 29 months). The therapeutic effect seemed unrelated to a family history of tremor, the effect of alcohol, or the responsiveness to propranolol or primidone. Methazolamide may be an effective drug in the treatment of some patients with essential tremor, particularly those with head and voice tremor." @default.
• W1991562979 created "2016-06-24" @default.
• W1991562979 creator A5004605257 @default.
• W1991562979 creator A5068468412 @default.
• W1991562979 creator A5081329835 @default.
• W1991562979 creator A5091336684 @default.
• W1991562979 date "1991-10-01" @default.
• W1991562979 modified "2023-09-26" @default.
• W1991562979 title "Treatment of Essential Tremor With Methazolamide" @default.
• W1991562979 cites W1967359525 @default.
• W1991562979 cites W1967716985 @default.
• W1991562979 cites W1968801272 @default.
• W1991562979 cites W1971703016 @default.
• W1991562979 cites W1983351591 @default.
• W1991562979 cites W1991803473 @default.
• W1991562979 cites W1995199937 @default.
• W1991562979 cites W1997607664 @default.
• W1991562979 cites W2021000649 @default.
• W1991562979 cites W2023845492 @default.
• W1991562979 cites W2024813890 @default.
• W1991562979 cites W2025735554 @default.
• W1991562979 cites W2034357334 @default.
• W1991562979 cites W2052591648 @default.
• W1991562979 cites W2053661253 @default.
• W1991562979 cites W2055082101 @default.
• W1991562979 cites W2058866143 @default.
• W1991562979 cites W2059360227 @default.
• W1991562979 cites W2061004160 @default.
• W1991562979 cites W2062830994 @default.
• W1991562979 cites W2068042424 @default.
• W1991562979 cites W2079401194 @default.
• W1991562979 cites W2100185980 @default.
• W1991562979 cites W2100224938 @default.
• W1991562979 cites W2118262335 @default.
• W1991562979 cites W2121936014 @default.
• W1991562979 cites W2125154799 @default.
• W1991562979 cites W2138416238 @default.
• W1991562979 cites W2156281416 @default.
• W1991562979 cites W2157195616 @default.
• W1991562979 cites W2166940567 @default.
• W1991562979 cites W2309415430 @default.
• W1991562979 cites W2412771116 @default.
• W1991562979 cites W2413186126 @default.
• W1991562979 cites W2417004841 @default.
• W1991562979 cites W4229555253 @default.
• W1991562979 cites W4241987749 @default.
• W1991562979 cites W8694202 @default.
• W1991562979 doi "https://doi.org/10.1016/s0025-6196(12)61721-2" @default.
• W1991562979 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1921495" @default.
• W1991562979 hasPublicationYear "1991" @default.
• W1991562979 type Work @default.
• W1991562979 sameAs 1991562979 @default.
• W1991562979 citedByCount "42" @default.
• W1991562979 countsByYear W19915629792012 @default.
• W1991562979 countsByYear W19915629792013 @default.
• W1991562979 countsByYear W19915629792017 @default.
• W1991562979 countsByYear W19915629792019 @default.
• W1991562979 countsByYear W19915629792020 @default.
• W1991562979 countsByYear W19915629792021 @default.
• W1991562979 countsByYear W19915629792022 @default.
• W1991562979 crossrefType "journal-article" @default.
• W1991562979 hasAuthorship W1991562979A5004605257 @default.
• W1991562979 hasAuthorship W1991562979A5068468412 @default.
• W1991562979 hasAuthorship W1991562979A5081329835 @default.
• W1991562979 hasAuthorship W1991562979A5091336684 @default.
• W1991562979 hasConcept C118552586 @default.
• W1991562979 hasConcept C126322002 @default.
• W1991562979 hasConcept C141071460 @default.
• W1991562979 hasConcept C187212893 @default.
• W1991562979 hasConcept C197934379 @default.
• W1991562979 hasConcept C2775858608 @default.
• W1991562979 hasConcept C2777992146 @default.
• W1991562979 hasConcept C2778186239 @default.
• W1991562979 hasConcept C2778715236 @default.
• W1991562979 hasConcept C2779034229 @default.
• W1991562979 hasConcept C2780112193 @default.
• W1991562979 hasConcept C2780580376 @default.
• W1991562979 hasConcept C42219234 @default.
• W1991562979 hasConcept C71924100 @default.
• W1991562979 hasConcept C99508421 @default.
• W1991562979 hasConceptScore W1991562979C118552586 @default.
• W1991562979 hasConceptScore W1991562979C126322002 @default.
• W1991562979 hasConceptScore W1991562979C141071460 @default.
• W1991562979 hasConceptScore W1991562979C187212893 @default.
• W1991562979 hasConceptScore W1991562979C197934379 @default.
• W1991562979 hasConceptScore W1991562979C2775858608 @default.
• W1991562979 hasConceptScore W1991562979C2777992146 @default.
• W1991562979 hasConceptScore W1991562979C2778186239 @default.
• W1991562979 hasConceptScore W1991562979C2778715236 @default.
• W1991562979 hasConceptScore W1991562979C2779034229 @default.
• W1991562979 hasConceptScore W1991562979C2780112193 @default.
• W1991562979 hasConceptScore W1991562979C2780580376 @default.
• W1991562979 hasConceptScore W1991562979C42219234 @default.
• W1991562979 hasConceptScore W1991562979C71924100 @default.
• W1991562979 hasConceptScore W1991562979C99508421 @default.
• W1991562979 hasIssue "10" @default.
• W1991562979 hasLocation W19915629791 @default.
• W1991562979 hasLocation W19915629792 @default.

• next